Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Industriels
  2. Médicament
  3. BUTAZOLIDINE (phénylbutazone)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

BUTAZOLIDINE (phénylbutazone)

Medicine - Posted on Sep 16 2011 - Updated on Jun 12 2019
Active substance (DCI)
  • phénylbutazone
history (2)
  • 4/27/11

    BUTAZOLIDINE (phénylbutazone)

    Avis défavorable au remboursement en raison de son risque hématologique dans toutes ses indications BUTAZOLIDINE comprimé es...
    icône flèche
  • 1/18/06

    BUTAZOLIDINE 100 mg, comprimé enrobéBoite de 20 comprimés (301 634-9)BUTAZOLIDINE 250 mg, suppositoireBoite de 5 suppositoires (301 636-1)

    BUTAZOLIDINE 100 mg, comprimé enrobéBoite de 20 comprimés (301 634-9)BUTAZOLIDINE 250 mg, suppositoireBoite de 5 suppositoires (301 636-1)
    icône flèche
Technical information
ATC code
  • M01AA01
Manufacturer
Laboratoire NOVARTIS PHARMA S.A.S.
Presentation

BUTAZOLIDINE 100 mg, comprimé enrobé Boîte de 20 - Code CIP : 3016349

All our publications
    Drug therapy Joint and rheumatic diseases Paediatrics Pain - Inflammation Skin and connective tissue diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
eNq9mF1v2jAUhu/5FVHuSQKjJUyBamPthtSqjBZt2k1lkkMxc+3UH3zs188hdEsrR21N3UvscM6Jz3sev0pysrkj3gq4wIz2/VYQ+R7QlGWY3vb96fVZM/ZPBo1kiVao8lg3iIJW2/dSgoTo+8VuMANERfDz4vwL6P8D9wcNL2GzJaTy0XNKYhJ8Q2JxgfLiGS9ZMZx5dyAXLOv7uZK7VS8RkusqBmvGf4scpZCE+5Xq7vKmU11PwiLYC6IqAfwc0VtjUKBWMVPFOVA5RBJuGd8aQ8/Tm3bcPY6i2CoFFhMQTPEUxkguxpytcAaZORMiAqySzNfZFfAVAVkkMQYPl+mdsAqOlmgzgfuRuehPencoN7IZNVvdTi+KO73ecbtr12NeOSqzePRLhHnOs5t2Lz5qxVEINJwpif4wgvUIQDNfAN2ScomCZcvGjEtEHDULi+Fj2TnKw+H+WVFkWOQEbYOlyG2PCnGkt4FrOLh7keINrrnGFdFn9iQ+VYSEr6x6uoeJo4oLVg2ZorKGKWcT24MYMiphU99ROwzKzV6LGMTbhX06gP82xmpGcGpLOs0iBUJOJ6N60L0DIz4jAVPuDhI/MM3YWrw9fKrNdlR9vuOnMajuS6tozHHr6Mh6tn7pttXcR6eKsxxCjSUsDqHNiM7ZoZzRYjWHepCqa5XuPBNLEYEa19S0JJGW54PJczYA7oar3DAG/Xp6baua7wr49mr30xgaZ/1qv+1I7QL/Wqa1tb9e9OXsv8BSd+IPbTtVczNaFlLm4mMYrtfrYIFEUyB9WMGcv9eNULmb3fl8JwagNEQlVR2VPiuvy9c1znYUn7MIh9re/f/39tqYQ3IFB/SipLYzto5O3x7X/z2vs7LHj9jiLs3OnyKJGXVlkNTM7I4OvSB0a+kZ14y4nM9xzReYWmkmYfn1Z9BIwuLLz6DxF64DERg=
WvhTtKVrKrULNSC1